Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies?

摘要: Humanizing xenogenic monoclonal antibodies (MAbs) by genetic engineering has greatly improved their therapeutic utility and efficacy. The chimeric CD20 MAb C2B8 (Rituximab) is a prominent representative of this new generation MAbs been proposed as treatment choice for recurrent follicular non-Hodgkin's lymphomas. Treatment CD20+ B cells with triggers several cell-damaging actions including complement-mediated lysis (CDL), antibody-dependent cellular cytotoxicity (ADCC), MAb-induced induction apoptosis. We provide an overview the most mechanisms underlying efficacy antibody treatment. introduce our concept cross-priming cytotoxic T-cell responses promoted apoptosis incucing antibodies. tumor that are capable inducing proapoptotic signal via cell surface target structure may not only contribute to direct killing but also induce against tumor, which have long-lasting protective effect. report, using example anti-CD20 lymphoma cells, C2B8-induced kills these promotes uptake cross-presentation cell-derived peptides antigen-presenting dendritic (DC), induces maturation DC, allows specific CTL.